Resources

The brochures, whitepapers, publications, posters and videos, in this section will enable you to learn more about our Solupore system. Please do not hesitate to contact us to discuss your requirements further.

Avectas Cytotherapy

Find out more about a novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.

Download File

Avectas Plusone

Find out more about our Vector-free intracellular delivery by reversible permeabilization.

Download File

Avectas Solupore SUS (video)

Watch our informative video and find out more about the Avectas Solupore SUS system and how it is used.

Download File

Avectas WhitePaper

Find out how Solupore® by Avectas offers an automated, reproducible transfection system for the delivery of a wide variety of cargo (RNA, DNA, protein) to primary immune cells used in clinical cell therapy applications.

Download File

Non-viral delivery platform for cell engineering

Download our PDF and see how Solupore is accelerating the future of cell therapies through healthier and more functional cells for patients.

Download File

Avectas Opens new Labs in Cherrywood

Dr. Jamie Frankish presented at ISCT Vancouver 2024. “Novel non-viral delivery technology, Solupore®, enables gene delivery for a healthier, more potent, and significantly more effective CAR-T therapy in vivo.”

The Advanced Therapies Week 2024 Miami, featured our own Dr. Lisa O’Flynn as a guest speaker at the Non-Viral Solutions for Gene Therapy Session.

January 9, 2024
admin-avectas
News
0 Comments

Avectas announces the appointment of Dr. Ann Brady as Chief Business Officer

February 1, 2023
admin-avectas
News
0 Comments

Leading the commercialization of the Solupore® Platform for Next-Generation Gene-Modified Cell Therapies with Superior Cell Health and Functionality DUBLIN, Ireland and Cambridge MA, USA, 1st February 2023: Avectas, a cell engineering technology business, announces the appointment of Dr.Ann Brady as…

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next- Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

January 16, 2023
admin-avectas
News
0 Comments

DUBLIN, Ireland and CAMBRIDGE, MA – 16 January 2023: Avectas, a cell engineering technology leader, announces the launch of the Solupore® platform at the Advanced Therapies Week, Miami Beach Convention Centre, January 17th - 20th, 2023, Booth # 331. The…

Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology

December 29, 2022
admin-avectas
News
0 Comments

DUBLIN, Ireland and TORONTO, Canada, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and associated technologies for clinical and commercial…

Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors

Collaboration brings together Avectas' breakthrough cell engineering technology and Inceptor Bio's CAR-T platform MORRISVILLE, N.C. and DUBLIN, Oct. 12, 2022 /PRNewswire/ -- Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to…

GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process

The two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components; the goal is to improve the editing efficiency and cell viability of non-viral based cell therapies. PISCATAWAY, N.J. and DUBLIN, Sept.…

AVECTAS leading the way in non-viral cell engineering technology

H2020 Case Study: AVECTAS Case Study Cellular immunotherapy is an exciting new approach to treating cancer that offers hope to millions of people worldwide as it has the potential to cure the disease without the harsh side effects of treatments…

Killer cells: delivering a knockout blow to cancers

Irish scientists and companies are working on next-generation cancer therapies. A revolutionary treatment in cancer treatment will see immune cells injected into patients. Already there are five approved therapies that take T cells out of cancer patients, genetically edit them…

Page 1
Page 2
Next